Evidence map›Paper›PMID 39580640›Full record

ArticleFuture medicinal chemistry2024

New pyrano-pyridine conjugates as potential anticancer agents: design, synthesis and computational studies.

Aladdin M Srour, Eman S Nossier, Najla A Altwaijry, Safeya M Mousa, Hanem M Awad, Heba S A Elzahabi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aladdin M SrourDepartment of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Giza, Egypt.
Eman S NossierDepartment of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.
Najla A AltwaijryDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Safeya M MousaDepartment of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.
Hanem M AwadTanning Materials and Leather Technology Department, National Research Centre, Giza, Egypt.
Heba S A ElzahabiDepartment of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimNew pyrano[3,2-c]pyridine 4a-h, 5-8 and pyrano[2,3-d]pyrimidin 9a,b series were designed and chemically synthesized. METHODOLOGY: Using the standard drug doxorubicin, the novel chemical entities have been assessed in vitro as potential anticancer prospects on cell lines from liver, breast, colon, and lung cancer along with examining their inhibitory behaviors upon both EGFR and VEGFR-2 kinases. RESULTS &

conclusionCompared to erlotinib (IC

Indexed as

Antineoplastic AgentsDrug DesignDrug Screening Assays, AntitumorErbB ReceptorsProtein Kinase InhibitorsPyransPyridinesVascular Endothelial Growth Factor Receptor-2Cell Line, TumorCell ProliferationHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsEGFR protein, humanErbB ReceptorsKDR protein, humanProtein Kinase InhibitorsPyransPyridinesVascular Endothelial Growth Factor Receptor-2anti-cancerapoptosisEGFRPyrano[3,2-c]pyridineVEGFR-2

Identifiers

PMID39580640
PMCPMC11734389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.